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ABSTRACT
Introduction: To investigate the clinical effects
associated with premixed insulin (PM) and basal
insulin [insulin NPH (NPH), insulin glargine
(IG), insulin detemir (ID)], in insulin-naı¨ve
patients with type 2 diabetes in routine
clinical care.
Materials and Methods: Cohort study based on
data from the Swedish National Diabetes
Register, including 5,077 patients, resident in
the Western region of Sweden. Patients were
included between 1 July 2006 and 31 December
2009 and followed for 12 months. Changes in
HbA1c, body mass index (BMI) and required
insulin doses were compared between the
different insulin types. Covariance
adjustments were performed to adjust for
differences between the groups.
Results: NPH, IG, ID and PM were all associated
with significant reductions in HbA1c,
mean ± standard deviation ranged between
6.6 ± 17.4 mmol/mol (IG) and
8.9 ± 17.7 mmol/mol (NPH), during the
12 months of follow-up. There were no
statistically significant differences in the
magnitude of HbA1c reduction between the
insulin types. PM required 59% higher and ID
25% higher insulin doses to achieve a similar
HbA1c reduction as NPH. PM was associated
with a significantly greater increase in BMI
compared with NPH (p = 0.016), while IG and
ID did not differ significantly from NPH. The
number of patients experiencing severe
hypoglycemia was low, but highest in patients
treated with PM (p = 0.023).
Conclusions: NPH, IG, ID and PM were found
to be equally effective in lowering HbA1c in
insulin-naı¨ve patients with type 2 diabetes in
routine clinical care in Sweden. The effects on
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weight, dose and treatment persistence support
the recommendation of NPH or IG as first and
second choices in this group of patients
requiring initiation of insulin treatment.
Keywords: Basal insulin; Glycosylated
hemoglobin; Insulin detemir; Insulin glargine;
Neutral protamine Hagedorn; Premixed insulin;
Type 2 diabetes
INTRODUCTION
Current international guidelines promote the
use of insulin treatment in patients with type 2
diabetes (T2D) when lifestyle changes and oral
hypoglycemic agents (OHA) fail to achieve
adequate glycemic control [1–3]. It is usually
recommended to start with a basal insulin at
bedtime, i.e., the medium long-acting neutral
protamine Hagedorn (NPH) or a long-acting
insulin analog [insulin glargine (IG) or insulin
detemir (ID)], but premixed insulin (PM),
usually administered twice daily, is a
frequently used alternative [4]. IG and ID are
advocated particularly in patients experiencing
nocturnal hypoglycemia [1, 2], while the latter
has been shown to require higher doses to
achieve similar metabolic effects [5].
The clinical effects of these different
insulin treatment regimens have been
evaluated in randomized clinical trials (RCT)
and subsequent meta-analyses, which together
constitute the foundation of the treatment
guidelines. Usually only RCTs are included in
meta-analyses [6, 7]. Thus, the effects in
clinical practice have generally not been
described, although there are a small number
of retrospective cohort studies that have
evaluated different insulin therapies
clinically [8–11]. One study compared
different insulin-treatments in 4,337 insulin-
naı¨ve patients with T2D initiating on NPH,
PM, IG, or ID in routine clinical practice,
using a retrospective database approach [The
Health Improvement Network (THIN)
database] [12]. Glycosylated hemoglobin
(HbA1c), weight gain and insulin dose were
evaluated during 12 months and persistence
during 36 months, showing that patients
initiating on NPH experienced a modest
disadvantage in glycemic control, IG
achieved best HbA1c reduction, while PM
showed greatest weight gain and highest
insulin dose, but showed superior persistence.
The authors initiated this register-based
project to study the effects of four insulin
regimens in 5,077 insulin-naı¨ve patients with
T2D, resident in the geographical region of
Western Sweden (Region Va¨stra Go¨taland),
the clinical effects, such as changes in
HbA1c and body mass index (BMI), insulin
dose, and frequencies of hypoglycemia.
Another aim of the project was to investigate
health care utilization and costs, but these
results will be presented in a subsequent
report.
METHODS
This is a retrospective cohort study based on
information retrieved from four national health
registers: the Swedish National Diabetes Register
(NDR), the Prescribed Drug Register, the Cause
of Death Register and the Regional Claims
Database (VEGA) of the Region Va¨stra
Go¨taland. All procedures followed were in
accordance with the ethics review board at the
University of Gothenburg and with the Helsinki
Declaration of 1975, as revised in 2000 and
2008. All included patients have agreed by
informed consent to be registered before
inclusion.
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Databases
NDR was initiated in 1996 to enable local
quality control and regional benchmarking
against national treatment guidelines [13].
Trained physicians and nurses via the Internet
or clinical record databases carry out annual
reporting to the NDR during patient visits at
hospitals and primary health care centers
nationwide. Thus, clinical data such as BMI,
HbA1c, and debut of diabetes were collected
from NDR. The Prescribed Drug Register (PDR)
contains full coverage of all filled drug
prescriptions (pharmaceutical agents and
amounts) at pharmacies in Sweden [14]. The
Cause of Death Register contains information
about causes of mortality and death dates [15]
and the VEGA database comprises information
about diagnoses [International Classification of
Diseases (ICD)-10 and Diagnosis Related Groups
(DRG) codes], performed procedures [Nordic
Medico-Statistical Committee (NOMESCO) and
local procedure codes] and hospital length of
stay for inpatient, outpatient, primary, and
private care for all inhabitants in the Region
Va¨stra Go¨taland.
Inclusion and Exclusion Criteria
Insulin-naı¨ve patients with T2D resident in the
Region of Va¨stra Go¨taland, who were at least
18 years old and initiated continuous use of
basal insulin (NPH, IG, ID) or PM, were included
(Fig. 1). The definition of T2D was treatment
with diet only, OHA only, or onset age of
diabetes C40 years and treatment with insulin
only or combined with OHA. Insulin-naı¨ve
patients were identified by exclusion of
patients who had a prescription of any type of
insulin filled between 1 July 2005 and 30 June
2006.
Study Period, Follow-up and Censoring
The study period was between 1 July 2005 and
31 December 2010. Patients were required to
have their first prescription of insulin filled
(index date) between 1 July 2006 and 31
Fig. 1 Patient disposition. Stages of inclusion and exclusion
of patients, and used databases. ID insulin detemir, IG
insulin glargine, NDR National Diabetes Register, NPH
neutral protamine Hagedorn, PM premixed insulin, PDR
prescribed drug register, VEGA Regional Claims Database
of the Region Va¨stra Go¨taland
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December 2009 to allow for 1 year of follow-up.
Patients were thus followed for 12 months or
until the occurrence of a censoring event. Start
of follow-up was defined as the date of the first
filled insulin prescription (index date) in each
patient. Censoring events included a filled
prescription of a new type of insulin (NPH, IG,
ID or PM), death or move out of the Region
Va¨stra Go¨taland.
Patient Characteristics
Variables measured at baseline (index date)
included: age, gender, level of income,
diabetes duration, previous OHA usage, a
history of diabetes complications, or
cardiovascular disease (CVD). The latest
HbA1c- and BMI-values up to 6 months before
index date were used for this. To calculate the
levels of these variables at the end of the follow-
up period, the authors used the values closest,
i.e., values within a period ranging 3 months
prior to and 3 months following end of follow-
up. History of CVD was defined as diagnosis of
ischemic heart disease (I20–I25), atrial
fibrillation (AF) (I48), congestive heart failure
(CHF) (I50), or stroke (I61, I63, I64, I67.9) prior
to the index date. History of diabetes
complications was defined as diagnosis of
diabetic ulcer (E11.62), neuropathy (E11.4),
nephropathy (E11.2) or microalbuminuria
(urine albumin excretion rate [20 lg/min in
two of three consecutive tests) prior to the
index date. History of OHA usage was defined as
at least one filled prescription of any OHA
between 1 July 2005 and index date.
Furthermore, the number of different OHAs
prescribed during this period was taken into
account. Median income for different
municipalities of residence were retrieved from
Statistics Sweden, and divided into quartiles
ranging from high to low income.
Outcomes
This investigation studied changes in HbA1c
and in BMI and number of hypoglycemic
events. A hypoglycemic event was defined as
ICD-10-codes E10.0C, E11.0C, E16.0, E16.1,
E16.1W and E16.2 to capture all possible cases.
Furthermore, mean daily insulin doses were
calculated in each group as the total prescribed
dose during follow-up divided by the number of
days between index date and end of follow-up.
Mean insulin doses per day and kilogram were
calculated for patients with available
information on weight. Analyses of HbA1c
were carried out at local laboratories. During
the study period, HbA1c analyses were quality
assured nationwide by regular calibration with
the high-performance liquid chromatography
Mono-S method.
Statistical Methods
Baseline characteristics are presented as
means ± 1 standard deviation (SD) or medians
for continuous variables and frequencies for
categorical variables with crude significance
levels for differences between the groups,
when analyzed using ANOVA or v2 test
(Table 1). For continuous variables with non-
normal distribution, a Kruskal–Wallis test was
performed. All continuous outcome variables
were explored for their distribution. A
correlation analysis was performed between
pre-index and post-index values for HbA1c
and BMI, in order to determine the strength of
the correlation and the appropriate means of
analysis. If the correlation coefficient exceeded
0.5, the incremental value (change from pre- to
post-index) was used in the regression, while
the pre-index value was included as a covariate
in the regression in cases with lower correlation
coefficients.
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The authors performed multivariate analysis
of the outcomes post-index HbA1c (mmol/mol),
incremental BMI (kg/m2) and daily insulin
dose (units/day kg), using generalized linear
modeling. For each outcome, three models
were explored and presented: firstly,
unadjusted where outcome was as a function
of insulin groups; secondly, including
covariates with few missing values (age,
gender, level of income, diabetes duration,
history of CVD, history of diabetes
complications, previous OHA use, and follow-
up time); and finally, a fully adjusted model
including age, gender, level of income, diabetes
duration, history of CVD, history of diabetes
complications, previous OHA use, follow-up
time, pre-index HbA1c, pre-index BMI and
weight. Some covariates were not considered
appropriate to include for all outcomes. Follow-
up time was only included as a covariate when
evaluating HbA1c, and BMI, while for
evaluating daily insulin dose and censoring,
follow-up time was either intrinsic to the
outcome or used for estimating the outcome.
For the same reason, weight was only included
for HbA1c and censoring.
All statistical analyses were performed in SAS
V.9.3 (SAS Institute, Cary, North Carolina,
USA). A two-sided p value \0.05 was
considered statistically significant.
RESULTS
In total, 5,077 insulin-naı¨ve patients with T2D
were included in the study. The majority were
initiated on NPH (49%) or PM (34%), while 13%
and 3% were initiated on IG and ID,
respectively. There were overall significant
differences in clinical characteristics between
the groups (Table 1), but we did not compare
the different groups separately. Those initiated
on ID were numerically youngest with the
lowest proportions of CVD and diabetes
complications, while patients receiving PM
were the oldest and had the highest
proportions of CVD and diabetes
complications. Patients initiated on NPH and
IG were quite similar in clinical characteristics,
with about 60% males, a mean age of about
65 years, a history of CVD in approximately
one-third and diabetes complications in about
half of the patients, but with a longer diabetes
Table 1 Clinical characteristics
NPH
(n5 2,490)
IG (n5 680) ID (n5 158) PM
(n5 1,749)
p value
Male gender (%) 61 59 56 55 0.0017
Age [years (mean ± SD)] 65 ± 13 64 ± 14 59 ± 14 71 ± 13 \0.001
Diabetes duration [years (mean ± SD)] 7.5 ± 6.0 8.6 ± 7.1 7.6 ± 5.5 8.4 ± 6.5 \0.001
History of CVD (%) 34 32 22 44 \0.001
History of diabetes complications (%) 47 46 32 50 \0.001
OHA use (%) 77 80 84 77 0.065
Number of OHA (mean ± SD) 1.4 ± 1.0 1.6 ± 1.1 1.6 ± 1.1 1.4 ± 1.1 \0.001
CVD cardiovascular disease, ID insulin detemir, IG insulin glargine, NPH neutral protamine Hagedorn, OHA oral
hypoglycemic agent, PM premixed insulin, SD standard deviation
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duration in the IG group (8.6 ± 7.1 years
compared to 7.5 ± 6.0 years).
Differences in mean follow-up time between
the groups were small but statistically
significant, with follow-up time ranging from
351 ± 51 days in ID to 358 ± 37 days in IG
(Table 2). The proportion of patients censored
due to any cause was lowest in IG, mostly due to
less treatment switches (3.1%) compared to
NPH (6.9%), ID (8.2%) and PM (4.6%). There
were significant differences in censoring due to
death, with the highest proportion seen in PM
(4.5%) and the lowest proportion seen in ID
(0.6%). However, this analysis was not adjusted
for differences in clinical characteristics
between the groups.
Table 3 describes mean ± SD for HbA1c and
BMI at baseline, end of follow-up, as well as
unadjusted changes in HbA1c and BMI during
follow-up in the different groups. HbA1c levels
at baseline ranged between 67 ± 16 mmol/mol
(PM) and 68 ± 17 mmol/mol (NPH) with no
statistically significant differences between the
groups. Change in HbA1c also did not differ
significantly between the groups, ranging
between -7 ± 17 mmol/mol (IG) and -9 ± 18
mmol/mol (NPH). The non-significant
differences in change of HbA1c remained
when IG, ID or PM was compared with NPH as
reference, adjusted for covariates. There were
small differences in BMI between the groups,
with patients treated with ID being most obese
(32.1 ± 7.1 kg/m2) and patients treated with PM
being least obese (29.5 ± 5.4 kg/m2) at baseline.
This pattern remained during the study even
though patients starting PM gained most
weight, with a change in BMI of 0.8 ± 2.3
kg/m2 compared to 0.4 ± 1.8, 0.3 ± 2.3 and
0.3 ± 2.3 kg/m2 in NPH, IG and ID,
respectively. When BMI change was compared
in IG, ID and PM with NPH as reference,
adjusted for covariates, the increase in BMI
remained significantly greater in PM, p = 0.016
(Tables 4, 5, 6).
There were significant differences in insulin
doses between the groups (Table 7). Among
patients receiving insulin in monotherapy, the
weight-adjusted doses were highest in PM and
ID. However, when doses of mealtime insulins
were taken into account, only ID required
higher doses. In patients treated with insulin
in combination with OHA, both ID and PM
required higher weight-adjusted doses even
when mealtime insulin use was taken into
account. NPH and IG required similar weight-
adjusted doses in patients receiving insulin in
monotherapy as well as in patients with insulin
in combination with OHA. Covariance-adjusted
comparisons of weight-adjusted daily insulin
doses with IG, ID or PM and NPH as reference
Table 2 Length of follow-up and censoring
NPH IG ID PM p value
Mean follow-up [days (mean ± SD)] 352 ± 47 358 ± 37 351 ± 51 352 ± 47 0.0099
Any censoring (n, %) 244, 9.8 39, 5.7 16, 10.1 165, 9.4 0.023
Censored due to death (n, %) 60, 2.4 16, 2.4 1, 0.6 78, 4.5 \0.001
Censored due to switch (n, %) 173, 6.9 21, 3.1 13, 8.2 81, 4.6 \0.001
Censored due to move (n, %) 11, 0.4 2, 0.3 2, 1.3 6, 0.3 NS
ID insulin detemir, IG insulin glargine, NPH neutral protamine Hagedorn, NS not signiﬁcant, OHA oral hypoglycemic
agent, PM premixed insulin, SD standard deviation
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showed that patients treated with ID and PM
required 59% and 25% higher doses, p\0.0001
(Table 6). The required insulin doses did not
differ significantly between IG and NPH.
Hypoglycemia requiring admission to a
hospital occurred infrequently. The total
number of patients experiencing severe
hypoglycemia was 26, with the largest
Table 3 Baseline values and changes in HbA1c and BMI
NPH (mean – SD) IG (mean – SD) ID (mean – SD) PM (mean – SD) p value
HbA1c pre-index (mmol/mol) 68 ± 17 67 ± 17 68 ± 17 67 ± 16 NS
HbA1c post-index (mmol/mol) 59 ± 12 61 ± 14 61 ± 16 59 ± 12 NS
HbA1c change (mmol/mol) -9 ± 18 -7 ± 17 -7 ± 18 -8 ± 17 NS
BMI pre-index (kg/m2) 30.9 ± 5.4 30.2 ± 5.4 32.1 ± 7.1 29.5 ± 5.4 0.0022
BMI post-index (kg/m2) 31.3 ± 5.4 30.5 ± 5.6 32.4 ± 7.2 30.3 ± 5.8 0.033
BMI change (kg/m2) 0.4 ± 1.8 0.3 ± 2.3 0.3 ± 2.3 0.8 ± 2.3 0.048
BMI body mass index, HbA1c glycosylated hemoglobin, ID insulin detemir, IG insulin glargine, NPH neutral protamine
Hagedorn, NS not signiﬁcant, PM premixed insulin, SD standard deviation
Table 4 Adjusted comparison of post-index HbA1c in IG, ID, PM vs. NPH
Post-index HbA1c
(mmol/mol)
Model 1, n5 2,534 Model 2, n 5 993 Model 3, n5 778
Change SD p value Change SD p value Change SD p value
IG vs. NPH 1.0 0.01 0.005 1.0 0.02 0.092 1.0 0.02 0.44
ID vs. NPH 1.1 0.02 0.000 1.0 0.04 0.57 1.0 0.04 0.43
PM vs. NPH 1.0 0.01 0.44 1.0 0.01 0.56 1.0 0.02 0.59
Multivariate analysis using generalized linear modeling. Model 1, unadjusted; Model 2, adjusted for covariates with few
missing values (age, gender, level of income, diabetes duration, history of CVD, history of diabetes complications, previous
OHA use, and follow-up time); Model 3, fully adjusted as Model 2 plus pre-index HbA1c, pre-index BMI and weight
BMI body mass index, HbA1c glycosylated hemoglobin, ID insulin detemir, IG insulin glargine, NPH neutral protamine
Hagedorn, OHA oral hypoglycemic agent, PM premixed insulin, SD standard deviation
Table 5 Adjusted comparison of BMI change of IG, ID, PM vs. NPH
Incremental BMI
(kg/m2)
Model 1 (n5 924) Model 2 (n 5 868) Model 3 (n5 759)
Change SD p value Change SD p value Change SD p value
IG vs. NPH -0.2 0.2 0.46 -0.2 0.2 0.40 -0.2 0.2 0.42
ID vs. NPH -0.1 0.4 0.77 -0.2 0.4 0.57 -0.3 0.4 0.44
PM vs. NPH 0.4 0.2 0.017 0.4 0.2 0.009 0.4 0.2 0.016
Multivariate analysis using generalized linear modeling. Model 1, unadjusted; Model 2, adjusted for covariates with few
missing values (age, gender, level of income, diabetes duration, history of CVD, history of diabetes complications, previous
OHA use, and follow-up time); Model 3, fully adjusted as Model 2 plus pre-index HbA1c, pre-index BMI and weight
BMI body mass index, HbA1c glycosylated hemoglobin, ID insulin detemir, IG insulin glargine, NPH neutral protamine
Hagedorn, OHA oral hypoglycemic agent, PM premixed insulin, SD standard deviation
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numbers in patients treated with NPH (n = 7
patients) and PM (n = 15; overall p = 0.023).
DISCUSSION
This observational study provides information
on clinical effects of different types of insulin in
a real-world setting. The included patients
demonstrated an HbA1c at baseline of
67–68 mmol/mol despite an average use of
more than one type of OHA, corresponding to
a stage of disease when insulin initiation is
recommended [16]. The results showed
significant reductions in HbA1c for patients
treated with NPH, IG, ID or PM during
12 months of follow-up, even though the
reductions were relatively modest. There was
no statistically significant difference in
the achieved change of HbA1c between the
different types of insulin. However, the required
insulin doses differed between the groups.
Patients treated with ID and PM required 59%
Table 6 Adjusted comparison in dose of IG, ID, PM vs. NPH
Daily insulin dose
(units/day kg)
Model 1, n5 3,591 Model 2, n5 3,350 Model 3, n5 1,193
Change SD p value Change SD p value Change SD p value
IG vs. NPH 1.1 0.03 0.056 1.0 0.03 0.25 1.0 0.052 0.77
ID vs. NPH 1.4 0.04 \0.0001 1.0 0.04 \0.0001 1.6 0.069 \0.0001
PM vs. NPH 1.2 0.02 \0.0001 1.2 0.02 \0.0001 1.2 0.036 \0.0001
Multivariate analysis using generalized linear modeling. Model 1, unadjusted; Model 2, adjusted for covariates with few
missing values (age, gender, level of income, diabetes duration, history of CVD, history of diabetes complications, previous
OHA use, and follow-up time); Model 3, fully adjusted as Model 2 plus pre-index HbA1c, pre-index BMI and weight
BMI body mass index, HbA1c glycosylated hemoglobin, ID insulin detemir, IG insulin glargine, NPH neutral protamine
Hagedorn, OHA oral hypoglycemic agent, PM premixed insulin, SD standard deviation
Table 7 Insulin doses
NPH IG ID PM p value
Insulin only
Dose (U/day) 28.1 (16.0) 28.7 (19.3) 34.2 (19.2) 39.8 (21.7) \0.001
Total insulin dose (U/day) 43.7 (26.9) 46.5 (32.2) 50.1 (24.5) 41.1 (22.3) 0.0186
Adjusted dose (U/day 9 kg weight) 0.34 (0.17) 0.34 (0.14) 0.42 (0.21) 0.52 (0.27) \0.001
Adjusted total insulin dose (U/day 9 kg weight) 0.55 (0.30) 0.57 (0.28) 0.69 (0.32) 0.53 (0.28) 0.0146
Insulin and OHA combination
Dose (U/day) 29.9 (17.9) 30.2 (17.0) 42.1 (29.0) 41.4 (24.7) \0.001
Total insulin dose (U/day) 34.5 (23.4) 34.8 (22.3) 51.2 (35.7) 42.4 (26.5) \0.001
Adjusted dose (U/day 9 kg weight) 0.33 (0.18) 0.33 (0.16) 0.45 (0.31) 0.47 (0.24) \0.001
Adjusted total insulin dose (U/day 9 kg weight) 0.38 (0.25) 0.39 (0.23) 0.56 (0.38) 0.47 (0.25) \0.001
ID insulin detemir, IG insulin glargine, NPH neutral protamine Hagedorn, OHA oral hypoglycemic agent, PM premixed
insulin, U insulin units
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and 25% higher weight-adjusted daily insulin
doses to achieve similar results on HbA1c when
compared with patients treated with NPH.
Patients treated with PM also gained more
weight, illustrated by their greater increase in
BMI during the study, compared with patients
treated with other types of insulin. The mean
number of days of follow-up was largest in IG.
The recorded number of patients experiencing a
hypoglycemic event was low (only 26 patients
in total), but occurred predominantly in
patients treated with premixed insulin.
The achieved HbA1c changes in the present
study were smaller than seen in previous
observational studies [10, 12, 17] and RCTs
[5, 18, 19]. The insulin doses in the present
study were in general similar or only slightly
lower than in these previous studies, and cannot
fully explain the modest HbA1c change.
However, patient characteristics at inclusion
differed significantly between these studies. For
example, HbA1c levels at the time of insulin
initiation were considerably lower in the present
study than in previous studies based on data from
routine clinical care [10, 12, 17]. Interestingly, a
meta-analysis including 38,803 patients from 87
RCTs found a quite strong positive relationship
between baseline Hba1c and the magnitude of
HbA1c change [20]. Similar relationship has been
reported from observational data [12]. Thus, the
relatively low HbA1c levels at baseline and
possibly fear of hypoglycemia might be
explanations to the modest HbA1c reductions
seen in the present study.
The present results are fairly consistent with
previous findings. The Treating to Target in Type 2
Diabetes (4-T) Study evaluated the efficacy of basal
insulin, prandial insulin, or biphasic (premixed)
insulin in insulin-naı¨ve patients with T2D [18].
After 1 year of follow-up, PM and prandial insulin
were superior to basal insulin in lowering HbA1c,
but at the cost of more frequent hypoglycemic
episodes and more weight gain [18]. However, at
3 years of follow-up the insulin regimens were
equally effective in controlling HbA1c, but the
lower rate of hypoglycemia in the basal insulin
group remained [21]. A recently published
propensity score-matched observational study
also found basal insulin and premixed insulin to
be equally effective in lowering HbA1c, but with
less weight gain and a lower rate of hypoglycemia
with basal insulin [17]. These studies, however, did
not distinguish between different types of basal
insulin. Consistent with results from meta-
analyses [6, 7, 22, 23] and RCTs [5], the present
study did not show significant differences in
achieved HbA1c reductions between NPH, IG or
ID, but with higher required doses for ID. Thus, the
finding of a slightly greater HbA1c reduction with
IGreported ina studybased on data from aprimary
care register in the United Kingdom was not
confirmed [12].
The difficulties of obtaining valid
information on hypoglycemia through
registers have been recognized in previous
observational studies. In the present study,
only 26 patients with hypoglycemia were
reported. This could be a substantial
underestimation of the total number of
hypoglycemia. However, the present data
support a higher frequency in patients treated
with PM [18] and possibly NPH, and also RCTs
demonstrating less hypoglycemic episodes in
patients treated with IG and ID compared to
NPH [6, 24].
The present study has several strengths. The
data were collected from the NDR database with
a currently estimated coverage of more than
90% of all patients in hospital outpatient clinics
and almost 80% of all patients in primary care
in Sweden, suggesting it to be highly
representative of clinical practice. The
observational design allows for comparisons of
the effectiveness of different types of insulin in
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a real-world setting, reflecting the results in
routine clinical care. Such studies constitute
important complementary information to
RCTs, which often show a high degree of
internal validity but at the cost of less
generalizability. However, the observational
design and absence of randomization involves
limitations including a risk of confounding by
indication, as well as the limited number of
patients on IG and ID, the latter in particular.
Despite comprehensive covariance adjustment
for relevant covariates in the present study, the
possibility of residual confounding due to
unknown and unmeasured covariates cannot
be ruled out. Furthermore, the lack of reliable
data on non-severe hypoglycemia is an
important limitation of the present study.
When considering benefits and risks of
glucose-lowering agents, the risk of
hypoglycemia and other important adverse
effects must be taken into account.
CONCLUSION
NPH, IG, ID and PM were found to be effective
agents in lowering HbA1c in insulin-naı¨ve
patients with T2D in routine clinical care. The
different types of insulin were equally effective
in lowering HbA1c, but with greater weight gain
and more hypoglycemia associated with PM,
and higher dose requirements for PM and ID.
The effects on weight, dose and treatment
persistence support the recommendation of
NPH or IG as first and second choices in this
group of patients requiring initiation of insulin
treatment.
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